The first lipodystrophy treatment for European patientsNovelion Therapeutics’ Myalepta (metreleptin) developed for the ultra-rare condition lipodystrophy has been approved by the European Commission, giving Share XThe first lipodystrophy treatment for European patientshttps://pharmaphorum.com/news/the-first-lipodystrophy-treatment-for-european-patients/